Bayer Challenges Generics' Profit Claims In Xarelto Dispute
Bayer argued at a London court Tuesday that a request from Sandoz that it hand over its profits from an invalidated blood-thinning patent should be rejected because this would go beyond what the...To view the full article, register now.
Already a subscriber? Click here to view full article